On June 17, the U.S. FDA authorized the Moderna pediatric vaccine for children 6 months to 5 years old under an Emergency Use Authorization (EUA), meaning the vaccine was proven safe and effective for this age group. This vaccine is a two-dose series, and the doses should be administered four weeks apart. Each dose is 25 mcg, one fourth of the dose approved for adults. In clinical trials while the highly contagious Omicron variant was circulating, vaccine efficacy against symptomatic infection was 50.6% for children 23 months and younger and 36.8% for children 2 years to under 6 years old.

See the U.S. FDA fact sheet for more information.